At last, an orally active gonadotropin-releasing hormone antagonist



Volume 111, Issue 1, Pages 30–31


Richard J. Paulson, M.D., M.S.


In July 2018 the U.S. Food and Drug Administration (FDA) approved, for the first time, an orally active gonadotropin-releasing hormone (GnRH) antagonist. My first thought was, I only wish that Gary Hodgen had lived long enough to see this day. I remember listening to his wonderfully prescient lectures on GnRH and its analogs in the early 1990s, dreaming of all that was going to be possible when the GnRH antagonists finally became a reality (1). Gary was a brilliant researcher and spent many years performing pioneering studies on prototypes of GnRH antagonists, which promised to transform reproductive medicine.

Read the full text here.

Go to the profile of Fertility and Sterility

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.